




Goat F(ab')₂ Anti-Human IgA

Cat. No.	Format	Size
2052-01	Purified (UNLB)	0.5 mg
2052-02	Fluorescein (FITC)	0.5 mg
2052-08	Biotin (BIOT)	0.5 mg
2052-09	R-phycoerythrin (PE)	0.25 mg
2052-31	Alexa Fluor [®] 647 (AF647)	0.5 mg
2052-32	Alexa Fluor [®] 555 (AF555)	0.5 mg



FLISA plate was coated with purified human IgA, IgG, and IgM. Immunoglobulins were detected with serially diluted Goat F(ab')₂ Anti-Human IgA-PE (SB Cat. No. 2052-09).

Description

Specificity	Reacts with the heavy chain of human IgA
Source	Pepsin digest of Goat Anti-Human IgA (SB Cat. No. 2050)
Cross Adsorption	Human IgG and IgM; may react with IgA from other species

Applications

Quality tested applications include –

ELISA^{1-4,6}
 FLISA
 FC⁹⁻¹⁶

Other referenced applications include –

ELISPOT⁵
 IHC-FS^{7,8}
 Stim¹⁷

Working Dilutions

ELISA	BIOT conjugate	1:5,000 – 1:20,000
FLISA	FITC conjugate	1:100 – 1:400
	AF555 conjugate	1:200 – 1:400
	PE and AF647 conjugates	≤ 1 µg/mL
Flow Cytometry	FITC and BIOT conjugates	≤ 1 µg/10 ⁶ cells
	PE and AF647 conjugates	≤ 0.1 µg/10 ⁶ cells
For flow cytometry, the suggested use of these reagents is in a final volume of 100 µL		
Other Applications	Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.	

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC), Alexa Fluor® 555 (AF555), and Alexa Fluor® 647 (AF647) conjugates are supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.25 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific (M)SDS.

References

1. Guttormsen H, Baker CJ, Edwards MS, Paoletti LC, Kasper DL. Quantitative determination of antibodies to type III group B streptococcal polysaccharide. *J Infect Dis.* 1996;173:142-50. (ELISA)
2. Matousovic K, Novak J, Yanagihara T, Tomana M, Moldoveanu Z, Kulhavy R, et al. IgA-containing immune complexes in the urine of IgA nephropathy patients. *Nephrol Dial Transplant.* 2006;21:2478-84. (ELISA)
3. Huggins J, Pellegrin T, Felgar RE, Wei C, Brown M, Zheng B, et al. CpG DNA activation and plasma-cell differentiation of CD27⁺ naive human B cells. *Blood.* 2007;109:1611-9. (ELISA)
4. Berthelot L, Papista C, Maciel TT, Biarnes-Pelicot M, Tissandie E, Wang PH, et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. *J Exp Med.* 2012;209:793-806. (ELISA)
5. Sira MM, Yoshida T, Takeuchi M, Kashiwayama Y, Futatani T, Kanegane H, et al. A novel immunoregulatory protein in human colostrum, syntenin-1, for promoting the development of IgA-producing cells from cord blood B cells. *Int Immunol.* 2009;21:1013-23. (ELISPOT)
6. White CA, Pone EJ, Lam T, Tat C, Hayama KL, Li G, et al. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. *J Immunol.* 2014;193:5933-50. (ELISA)
7. Boumediene A, Oblet C, Oruc Z, Duchez S, Morelle W, Huynh A, et al. Gammopathy with IgA mesangial deposition provides a monoclonal model of IgA nephritogenicity and offers new insights into its molecular mechanisms. *Nephrol Dial Transplant.* 2011;26:3930-7. (IHC-FS)
8. Burgener A, Tjernlund A, Kaldensjo T, Abou M, McCorrister S, Westmacott GR, et al. A systems biology examination of the human female genital tract shows compartmentalization of immune factor expression. *J Virol.* 2013;87:5141-50. (IHC-FS)
9. Grossetête B, Launay P, Lehuen A, Jungers P, Bach J, Monteiro RC. Down-regulation of Fcα receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. *Kidney Int.* 1998;53:1321-35. (FC)
10. Morton HC, van Zandbergen G, van Kooten C, Howard CJ, van de Winkel JG, Brandtzaeg P. Immunoglobulin-binding sites of human FcαRI (CD89) and bovine Fcγ2R are located in their membrane-distal extracellular domains. *J Exp Med.* 1999;189:1715-22. (FC)
11. Janoff EN, Fasching C, Orenstein JM, Rubins JB, Opstad NL, Dalmasso AP. Killing of *Streptococcus pneumoniae* by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. *J Clin Invest.* 1999;104:1139-47. (FC)
12. van der Pol W, Vidarsson G, Vilé HA, van de Winkel JG, Rodriguez ME. Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcαRI (CD89). *J Infect Dis.* 2000;182:1139-45. (FC)
13. Rodriguez ME, Hellwig SM, Hozbor DF, Leusen J, van der Pol W, van de Winkel JG. Fc receptor-mediated immunity against *Bordetella pertussis*. *J Immunol.* 2001;167:6545-51. (FC)
14. Honorio-Franca AC, Launay P, Carneiro-Sampaio MM, Monteiro RC. Colostral neutrophils express Fcα receptors (CD89) lacking γ chain association and mediate noninflammatory properties of secretory IgA. *J Leukoc Biol.* 2001;69:289-96. (FC)
15. Heystek HC, Moulon C, Woltman AM, Garonne P, van Kooten C. Human immature dendritic cells efficiently bind and take up secretory IgA without the induction of maturation. *J Immunol.* 2002;168:102-7. (FC)
16. Mota G, Manciuola M, Cosma E, Popescu I, Hirt M, Jensen-Jarolim E, et al. Human NK cells express Fc receptors for IgA which mediate signal transduction and target cell killing. *Eur J Immunol.* 2003;33:2197-205. (FC)
17. Toapanta FR, Bernal PJ, Sztejn MB. Diverse phosphorylation patterns of B cell receptor-associated signaling in naïve and memory human B cells revealed by phosphoflow, a powerful technique to study signaling at the single cell level. *Front Cell Infect Microbiol.* 2012;2:128. (Stim)

Alexa Fluor® 488, 647, and 555 are provided under an Intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.